Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Cynata Therapeutics.
RELATED STOCKHEAD STORIES
Experts
Scopo’s health powerplays: Clinical trials are back
Stockhead TV
StockTalk: Biotechs set to boom with clinical trial floodgates open
Health & Biotech
COVID-19 treatments are a better bet than a vaccine
News
10 at 10: These ASX stocks are shooting through the skies this morning
Health & Biotech
ATO blocks biotech access to Jobkeeper wage subsidy
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Are we mortgaging the future as COVID-19 closes clinical trials?
Health & Biotech
Dr Boreham’s Crucible: The small cap biotechs trying to make a buck from coronavirus
Health & Biotech
Biotech: It’s not a get-rich-quick scheme judging by these HY reports
Health & Biotech
Sepsis has tripled in Australia and these small caps are tackling it head on
Health & Biotech
Cancer Wars Part 1: These are the ASX small cap drugmakers that want to conquer cancer
Health & Biotech
Check up: Enthusiasm rather than news is moving health stocks
Health & Biotech
Biotech: Cynata wins first round against sepsis bugs
Health & Biotech
Health & Biotech: Mesoblast still not in the black, but they’re less in the red than last year
Health & Biotech
Health: Botanix buddy set to benefit after DEA admits their synthetic CBD is probably ok
Health & Biotech
These are the 22 small cap biotechs closest to bringing a drug to market
Health & Biotech
